PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-13.40%
Cash & equivalents declining -13.40% while CRVO's grows 193.69%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-13.40%
Below half of CRVO's 193.69%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.47%
Below half of CRVO's 205.96%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
8.92%
Below half CRVO's 99.38%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
55.91%
Below half of CRVO's 7035.41%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-12.20%
Below half of CRVO's 906.37%. Michael Burry sees a potential red flag for stagnation or capital shortage.
25.71%
Less than half of CRVO's 163.70%. David Dodd sees a more disciplined AP approach or lower volume.
-32.96%
Less than half of CRVO's -100.00%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-56.33%
Less than half of CRVO's 139.90%. David Dodd sees fewer expansions in other current obligations.
-28.78%
Less than half of CRVO's 50.04%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.78%
Less than half of CRVO's 173.15%. David Dodd sees far fewer liability expansions relative to competitor.
1.95%
Less than half of CRVO's 1161.60%. David Dodd sees fewer share issuances vs. competitor.
-3.92%
Below half CRVO's -14.76%. Michael Burry suspects major net losses or high dividends vs. competitor.
-19.50%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-8.72%
Below half CRVO's 39930.57%. Michael Burry sees potential underperformance in building shareholder capital.
-12.20%
Below half CRVO's 906.37%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-32.96%
50-75% of CRVO's -55.77%. Bruce Berkowitz sees relatively smaller yoy debt additions.
13.20%
Less than half of CRVO's -605.38%. David Dodd sees better deleveraging or stronger cash buildup than competitor.